A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
ACKR4 restrains antitumor immunity by regulating CCL21
2020
Journal of Experimental Medicine
concern
Current immunotherapies involving CD8+ T cell responses show remarkable promise, but their efficacy in many solid tumors is limited, in part due to the low frequency of tumor-specific T cells in the tumor microenvironment (TME). Here, we identified a role for host atypical chemokine receptor 4 (ACKR4) in controlling intratumor T cell accumulation and activation. In the absence of ACKR4, an increase in intratumor CD8+ T cells inhibited tumor growth, and nonhematopoietic ACKR4 expression was
doi:10.1084/jem.20190634
pmid:32289156
pmcid:PMC7971131
fatcat:4u6ruodxdzghbkeut4aqlxyila